ECM
APTO

Endurant Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Endurant Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,150
Closed -$3.09M – 82
2021
Q1 		$3.09M Buy
1,150
+88
+8% +$174K 0.81% 40
2020
Q4 		$2.09M Buy
1,062
+295
+38% +$693K 0.75% 41
2020
Q3 		$2.07M Buy
+767
New +$1.91M 0.61% 42

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Endurant Capital Management's APTO Position: Q2 2021 in Review

Endurant Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 1,150 shares — an estimated $3.09M sold.

Endurant Capital Management first reported a position in APTO in Q3 2020 and held it in 3 quarters. The position peaked at $3.09M in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Endurant Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Endurant Capital Management sold 1,150 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $3.09M.
  • Endurant Capital Management first reported a position in Aptose Biosciences, Inc. in Q3 2020 and held it in 3 quarters.
  • Endurant Capital Management's Aptose Biosciences, Inc. position peaked at $3.09M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Endurant Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.